Loading…

Anti-nucleosome antibodies in patients with systemic lupus erythematosus of recent onset. Potential utility as a diagnostic tool and disease activity marker

Objective. To compare the utility of anti-chromatin antibodies for the diagnosis of systemic lupus erythematosus (SLE) and as markers of disease activity. Methods. We included 73 consecutive patients (62 female) with SLE (four or more ACR criteria) of recent onset (

Saved in:
Bibliographic Details
Published in:Rheumatology (Oxford, England) England), 2004-02, Vol.43 (2), p.220-224
Main Authors: Simón, J. A., Cabiedes, J., Ortiz, E., Alcocer-Varela, J., Sánchez-Guerrero, J.
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c472t-8d09f535e5f0bdab5fb8d5c8ee05f169b5b3cd092b3f50498158e0935f14ae3f3
cites
container_end_page 224
container_issue 2
container_start_page 220
container_title Rheumatology (Oxford, England)
container_volume 43
creator Simón, J. A.
Cabiedes, J.
Ortiz, E.
Alcocer-Varela, J.
Sánchez-Guerrero, J.
description Objective. To compare the utility of anti-chromatin antibodies for the diagnosis of systemic lupus erythematosus (SLE) and as markers of disease activity. Methods. We included 73 consecutive patients (62 female) with SLE (four or more ACR criteria) of recent onset (
doi_str_mv 10.1093/rheumatology/keh024
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_80109689</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>80109689</sourcerecordid><originalsourceid>FETCH-LOGICAL-c472t-8d09f535e5f0bdab5fb8d5c8ee05f169b5b3cd092b3f50498158e0935f14ae3f3</originalsourceid><addsrcrecordid>eNqFkU1v1DAQhi0EomXhFyAhCwluae04zsexVJQiFbGHRUJcIseZdN068eJxoPkv_Fhm1aVIXJAP9ngezcf7MvZSihMpGnUatzCPJgUfrpfTW9iKvHjEjmVR5plQKn_88M6LI_YM8UYIoaWqn7IjqaQSUufH7NfZlFw2zdZDwDACNxR3oXeA3E18Z5KDKSH_6dKW44IJRme5n3czcohL2sJ-BKQoDDyCJZiHCSGd8HVIFDnj-Zycd2nhBrnhvTPXU8BEZVIInhr29IdgkJrb5H7sydHEW4jP2ZPBeIQXh3vFvly835xfZlefP3w8P7vKbFHlKat70QxaadCD6HrT6aGre21rAKEHWTad7pQlJu_UoEXR1FLXQApSsjCgBrVib-_r7mL4PgOmdnRowXszQZixrQUJXtbNf8Fc6Gp_CHz9D3gT5jjREq1sdFmKSu6rvTpAczdC3-6io72X9o87BLw5AAat8UM0k3X4l9NFLRqydMWye86RP3cPedKwLStV6fby67d2_eldsd6sdbtRvwEWibTP</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>195660719</pqid></control><display><type>article</type><title>Anti-nucleosome antibodies in patients with systemic lupus erythematosus of recent onset. Potential utility as a diagnostic tool and disease activity marker</title><source>Oxford Journals Online</source><source>Alma/SFX Local Collection</source><creator>Simón, J. A. ; Cabiedes, J. ; Ortiz, E. ; Alcocer-Varela, J. ; Sánchez-Guerrero, J.</creator><creatorcontrib>Simón, J. A. ; Cabiedes, J. ; Ortiz, E. ; Alcocer-Varela, J. ; Sánchez-Guerrero, J.</creatorcontrib><description>Objective. To compare the utility of anti-chromatin antibodies for the diagnosis of systemic lupus erythematosus (SLE) and as markers of disease activity. Methods. We included 73 consecutive patients (62 female) with SLE (four or more ACR criteria) of recent onset (&lt;1 yr since diagnosis). As control groups we included 130 healthy blood donors and 261 patients with 11 systemic autoimmune diseases (SAD). Disease activity was assessed using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). A venous blood sample was drawn to measure three anti-chromatin antibodies [anti-nucleosome (anti-NCS), anti-double-stranded DNA (anti-dsDNA) and anti-histones (anti-HST)] by enzyme-linked immunosorbent assay. Results. The prevalence of anti-chromatin antibodies in SLE patients and healthy controls was 100 and 3% respectively for anti-NCS, 63 and 5% for anti-dsDNA, and 15 and 3% for anti-HST. Anti-NCS had a sensitivity of 100% and specificity of 97% for SLE diagnosis. When SLE and SAD patients were compared [excluding mixed connective tissue disease (MCTD)], the sensitivity of anti-NCS, anti-dsDNA and anti-HST antibodies for SLE diagnosis was 93, 71 and 40% respectively and the specificity was 97, 98 and 98%. Anti-chromatin antibodies were not useful in differentiating between SLE and MCTD patients. Anti-NCS antibodies showed the highest correlation with disease activity (r = 0.45, P &lt; 0.0001), especially in patients negative for anti-dsDNA antibodies (r = 0.58, P = 0.001). Anti-NCS antibodies also showed strong association with renal damage (odds ratio 4.1, 95% confidence interval 1.2–13.6, P = 0.01). Conclusion. Anti-NCS antibodies could be a useful tool in the diagnosis and assessment of disease activity in SLE patients, especially in patients who are negative for anti-dsDNA antibodies.</description><identifier>ISSN: 1462-0324</identifier><identifier>EISSN: 1462-0332</identifier><identifier>DOI: 10.1093/rheumatology/keh024</identifier><identifier>PMID: 13130152</identifier><identifier>CODEN: BJRHDF</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Adolescent ; Adult ; Anti-chromatin antibodies ; Anti-nucleosome antibodies ; Antibodies, Antinuclear - blood ; Autoimmune Diseases - diagnosis ; Biological and medical sciences ; Biomarkers - blood ; Chromatin - immunology ; Cross-Sectional Studies ; Diagnosis ; Diagnosis, Differential ; Disease activity ; Diseases of the osteoarticular system ; Female ; Humans ; Lupus Erythematosus, Systemic - diagnosis ; Male ; Medical sciences ; Nucleosomes - immunology ; Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis ; Sensitivity and Specificity ; Severity of Illness Index ; Systemic lupus erythematosus</subject><ispartof>Rheumatology (Oxford, England), 2004-02, Vol.43 (2), p.220-224</ispartof><rights>2004 INIST-CNRS</rights><rights>Copyright Oxford University Press(England) Feb 2004</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c472t-8d09f535e5f0bdab5fb8d5c8ee05f169b5b3cd092b3f50498158e0935f14ae3f3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=15480951$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/13130152$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Simón, J. A.</creatorcontrib><creatorcontrib>Cabiedes, J.</creatorcontrib><creatorcontrib>Ortiz, E.</creatorcontrib><creatorcontrib>Alcocer-Varela, J.</creatorcontrib><creatorcontrib>Sánchez-Guerrero, J.</creatorcontrib><title>Anti-nucleosome antibodies in patients with systemic lupus erythematosus of recent onset. Potential utility as a diagnostic tool and disease activity marker</title><title>Rheumatology (Oxford, England)</title><addtitle>Rheumatology</addtitle><description>Objective. To compare the utility of anti-chromatin antibodies for the diagnosis of systemic lupus erythematosus (SLE) and as markers of disease activity. Methods. We included 73 consecutive patients (62 female) with SLE (four or more ACR criteria) of recent onset (&lt;1 yr since diagnosis). As control groups we included 130 healthy blood donors and 261 patients with 11 systemic autoimmune diseases (SAD). Disease activity was assessed using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). A venous blood sample was drawn to measure three anti-chromatin antibodies [anti-nucleosome (anti-NCS), anti-double-stranded DNA (anti-dsDNA) and anti-histones (anti-HST)] by enzyme-linked immunosorbent assay. Results. The prevalence of anti-chromatin antibodies in SLE patients and healthy controls was 100 and 3% respectively for anti-NCS, 63 and 5% for anti-dsDNA, and 15 and 3% for anti-HST. Anti-NCS had a sensitivity of 100% and specificity of 97% for SLE diagnosis. When SLE and SAD patients were compared [excluding mixed connective tissue disease (MCTD)], the sensitivity of anti-NCS, anti-dsDNA and anti-HST antibodies for SLE diagnosis was 93, 71 and 40% respectively and the specificity was 97, 98 and 98%. Anti-chromatin antibodies were not useful in differentiating between SLE and MCTD patients. Anti-NCS antibodies showed the highest correlation with disease activity (r = 0.45, P &lt; 0.0001), especially in patients negative for anti-dsDNA antibodies (r = 0.58, P = 0.001). Anti-NCS antibodies also showed strong association with renal damage (odds ratio 4.1, 95% confidence interval 1.2–13.6, P = 0.01). Conclusion. Anti-NCS antibodies could be a useful tool in the diagnosis and assessment of disease activity in SLE patients, especially in patients who are negative for anti-dsDNA antibodies.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Anti-chromatin antibodies</subject><subject>Anti-nucleosome antibodies</subject><subject>Antibodies, Antinuclear - blood</subject><subject>Autoimmune Diseases - diagnosis</subject><subject>Biological and medical sciences</subject><subject>Biomarkers - blood</subject><subject>Chromatin - immunology</subject><subject>Cross-Sectional Studies</subject><subject>Diagnosis</subject><subject>Diagnosis, Differential</subject><subject>Disease activity</subject><subject>Diseases of the osteoarticular system</subject><subject>Female</subject><subject>Humans</subject><subject>Lupus Erythematosus, Systemic - diagnosis</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Nucleosomes - immunology</subject><subject>Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis</subject><subject>Sensitivity and Specificity</subject><subject>Severity of Illness Index</subject><subject>Systemic lupus erythematosus</subject><issn>1462-0324</issn><issn>1462-0332</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><recordid>eNqFkU1v1DAQhi0EomXhFyAhCwluae04zsexVJQiFbGHRUJcIseZdN068eJxoPkv_Fhm1aVIXJAP9ngezcf7MvZSihMpGnUatzCPJgUfrpfTW9iKvHjEjmVR5plQKn_88M6LI_YM8UYIoaWqn7IjqaQSUufH7NfZlFw2zdZDwDACNxR3oXeA3E18Z5KDKSH_6dKW44IJRme5n3czcohL2sJ-BKQoDDyCJZiHCSGd8HVIFDnj-Zycd2nhBrnhvTPXU8BEZVIInhr29IdgkJrb5H7sydHEW4jP2ZPBeIQXh3vFvly835xfZlefP3w8P7vKbFHlKat70QxaadCD6HrT6aGre21rAKEHWTad7pQlJu_UoEXR1FLXQApSsjCgBrVib-_r7mL4PgOmdnRowXszQZixrQUJXtbNf8Fc6Gp_CHz9D3gT5jjREq1sdFmKSu6rvTpAczdC3-6io72X9o87BLw5AAat8UM0k3X4l9NFLRqydMWye86RP3cPedKwLStV6fby67d2_eldsd6sdbtRvwEWibTP</recordid><startdate>20040201</startdate><enddate>20040201</enddate><creator>Simón, J. A.</creator><creator>Cabiedes, J.</creator><creator>Ortiz, E.</creator><creator>Alcocer-Varela, J.</creator><creator>Sánchez-Guerrero, J.</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7QP</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20040201</creationdate><title>Anti-nucleosome antibodies in patients with systemic lupus erythematosus of recent onset. Potential utility as a diagnostic tool and disease activity marker</title><author>Simón, J. A. ; Cabiedes, J. ; Ortiz, E. ; Alcocer-Varela, J. ; Sánchez-Guerrero, J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c472t-8d09f535e5f0bdab5fb8d5c8ee05f169b5b3cd092b3f50498158e0935f14ae3f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Anti-chromatin antibodies</topic><topic>Anti-nucleosome antibodies</topic><topic>Antibodies, Antinuclear - blood</topic><topic>Autoimmune Diseases - diagnosis</topic><topic>Biological and medical sciences</topic><topic>Biomarkers - blood</topic><topic>Chromatin - immunology</topic><topic>Cross-Sectional Studies</topic><topic>Diagnosis</topic><topic>Diagnosis, Differential</topic><topic>Disease activity</topic><topic>Diseases of the osteoarticular system</topic><topic>Female</topic><topic>Humans</topic><topic>Lupus Erythematosus, Systemic - diagnosis</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Nucleosomes - immunology</topic><topic>Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis</topic><topic>Sensitivity and Specificity</topic><topic>Severity of Illness Index</topic><topic>Systemic lupus erythematosus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Simón, J. A.</creatorcontrib><creatorcontrib>Cabiedes, J.</creatorcontrib><creatorcontrib>Ortiz, E.</creatorcontrib><creatorcontrib>Alcocer-Varela, J.</creatorcontrib><creatorcontrib>Sánchez-Guerrero, J.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Rheumatology (Oxford, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Simón, J. A.</au><au>Cabiedes, J.</au><au>Ortiz, E.</au><au>Alcocer-Varela, J.</au><au>Sánchez-Guerrero, J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anti-nucleosome antibodies in patients with systemic lupus erythematosus of recent onset. Potential utility as a diagnostic tool and disease activity marker</atitle><jtitle>Rheumatology (Oxford, England)</jtitle><addtitle>Rheumatology</addtitle><date>2004-02-01</date><risdate>2004</risdate><volume>43</volume><issue>2</issue><spage>220</spage><epage>224</epage><pages>220-224</pages><issn>1462-0324</issn><eissn>1462-0332</eissn><coden>BJRHDF</coden><abstract>Objective. To compare the utility of anti-chromatin antibodies for the diagnosis of systemic lupus erythematosus (SLE) and as markers of disease activity. Methods. We included 73 consecutive patients (62 female) with SLE (four or more ACR criteria) of recent onset (&lt;1 yr since diagnosis). As control groups we included 130 healthy blood donors and 261 patients with 11 systemic autoimmune diseases (SAD). Disease activity was assessed using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). A venous blood sample was drawn to measure three anti-chromatin antibodies [anti-nucleosome (anti-NCS), anti-double-stranded DNA (anti-dsDNA) and anti-histones (anti-HST)] by enzyme-linked immunosorbent assay. Results. The prevalence of anti-chromatin antibodies in SLE patients and healthy controls was 100 and 3% respectively for anti-NCS, 63 and 5% for anti-dsDNA, and 15 and 3% for anti-HST. Anti-NCS had a sensitivity of 100% and specificity of 97% for SLE diagnosis. When SLE and SAD patients were compared [excluding mixed connective tissue disease (MCTD)], the sensitivity of anti-NCS, anti-dsDNA and anti-HST antibodies for SLE diagnosis was 93, 71 and 40% respectively and the specificity was 97, 98 and 98%. Anti-chromatin antibodies were not useful in differentiating between SLE and MCTD patients. Anti-NCS antibodies showed the highest correlation with disease activity (r = 0.45, P &lt; 0.0001), especially in patients negative for anti-dsDNA antibodies (r = 0.58, P = 0.001). Anti-NCS antibodies also showed strong association with renal damage (odds ratio 4.1, 95% confidence interval 1.2–13.6, P = 0.01). Conclusion. Anti-NCS antibodies could be a useful tool in the diagnosis and assessment of disease activity in SLE patients, especially in patients who are negative for anti-dsDNA antibodies.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>13130152</pmid><doi>10.1093/rheumatology/keh024</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1462-0324
ispartof Rheumatology (Oxford, England), 2004-02, Vol.43 (2), p.220-224
issn 1462-0324
1462-0332
language eng
recordid cdi_proquest_miscellaneous_80109689
source Oxford Journals Online; Alma/SFX Local Collection
subjects Adolescent
Adult
Anti-chromatin antibodies
Anti-nucleosome antibodies
Antibodies, Antinuclear - blood
Autoimmune Diseases - diagnosis
Biological and medical sciences
Biomarkers - blood
Chromatin - immunology
Cross-Sectional Studies
Diagnosis
Diagnosis, Differential
Disease activity
Diseases of the osteoarticular system
Female
Humans
Lupus Erythematosus, Systemic - diagnosis
Male
Medical sciences
Nucleosomes - immunology
Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis
Sensitivity and Specificity
Severity of Illness Index
Systemic lupus erythematosus
title Anti-nucleosome antibodies in patients with systemic lupus erythematosus of recent onset. Potential utility as a diagnostic tool and disease activity marker
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T09%3A25%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anti-nucleosome%20antibodies%20in%20patients%20with%20systemic%20lupus%20erythematosus%20of%20recent%20onset.%20Potential%20utility%20as%20a%20diagnostic%20tool%20and%20disease%20activity%20marker&rft.jtitle=Rheumatology%20(Oxford,%20England)&rft.au=Simo%CC%81n,%20J.%20A.&rft.date=2004-02-01&rft.volume=43&rft.issue=2&rft.spage=220&rft.epage=224&rft.pages=220-224&rft.issn=1462-0324&rft.eissn=1462-0332&rft.coden=BJRHDF&rft_id=info:doi/10.1093/rheumatology/keh024&rft_dat=%3Cproquest_pubme%3E80109689%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c472t-8d09f535e5f0bdab5fb8d5c8ee05f169b5b3cd092b3f50498158e0935f14ae3f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=195660719&rft_id=info:pmid/13130152&rfr_iscdi=true